Absolute first: OS +8.4 mo (21.1 vs 12.7), HR 0.42 — tarlatamab + durvalumab as 1L ES-SCLC maintenance. Also: PFS 7.4 vs 1.9; ORR 26.4% vs 4.1%; CRS ~50% mostly G1–2. Standing ovat

Mustafa Özdoğan, MD· @ozdogan_md · X·2026-10-25 01:47· 11 小时前评分70

正文 · 原文

Absolute first: OS +8.4 mo (21.1 vs 12.7), HR 0.42 — tarlatamab + durvalumab as 1L ES-SCLC maintenance. Also: PFS 7.4 vs 1.9; ORR 26.4% vs 4.1%; CRS ~50% mostly G1–2. Standing ovation at #ESMO26. Practice-changing — logistics of BiTE monitoring now the clinic question.

91 浏览 · 2 赞 · 2 转发 · 0 回复

会议摘要

3821P按 SCLC 对上

Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study

https://esmocongress.esmo.org

3848P按 SCLC 对上

Cytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis

https://esmocongress.esmo.org

LBA3按 Presidential Symposium I 对上

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

引用@

Presented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW @myESMO

在 X 查看被引用的帖子

来源：Mustafa Özdoğan, MD · x.com